Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | INDV |
---|---|---|
09:32 ET | 696 | 16.44 |
09:36 ET | 1463 | 16.5 |
09:38 ET | 1901 | 16.64 |
09:39 ET | 400 | 16.68 |
09:43 ET | 180 | 16.65 |
09:45 ET | 173 | 16.56 |
09:48 ET | 280 | 16.56 |
09:50 ET | 100 | 16.6 |
09:56 ET | 161 | 16.53 |
10:01 ET | 1434 | 16.57 |
10:10 ET | 228 | 16.57 |
10:15 ET | 200 | 16.57 |
10:17 ET | 300 | 16.56 |
10:19 ET | 248 | 16.6 |
10:21 ET | 100 | 16.59 |
10:24 ET | 300 | 16.57 |
10:26 ET | 102 | 16.57 |
10:30 ET | 200 | 16.52 |
10:32 ET | 239 | 16.531 |
10:33 ET | 815 | 16.53 |
10:42 ET | 100 | 16.52 |
10:44 ET | 325 | 16.54 |
10:46 ET | 250 | 16.55 |
10:51 ET | 400 | 16.55 |
10:57 ET | 100 | 16.57 |
11:06 ET | 449 | 16.616 |
11:08 ET | 3200 | 16.58 |
11:09 ET | 500 | 16.595 |
11:11 ET | 200 | 16.58 |
11:13 ET | 100 | 16.58 |
11:15 ET | 731 | 16.61 |
11:18 ET | 200 | 16.62 |
11:20 ET | 304 | 16.63 |
11:24 ET | 400 | 16.665 |
11:27 ET | 3300 | 16.67 |
11:29 ET | 700 | 16.68 |
11:36 ET | 100 | 16.61 |
12:27 ET | 135 | 16.58 |
12:36 ET | 100 | 16.51 |
12:41 ET | 100 | 16.555 |
01:06 ET | 247 | 16.5749 |
01:17 ET | 100 | 16.61 |
01:39 ET | 238 | 16.61 |
01:46 ET | 601 | 16.61 |
02:02 ET | 996 | 16.57 |
02:11 ET | 100 | 16.55 |
02:26 ET | 1000 | 16.59 |
02:27 ET | 100 | 16.54 |
02:47 ET | 100 | 16.56 |
03:02 ET | 100 | 16.55 |
03:03 ET | 100 | 16.55 |
03:18 ET | 100 | 16.555 |
03:27 ET | 728 | 16.56 |
03:32 ET | 400 | 16.59 |
03:36 ET | 1920 | 16.585 |
03:39 ET | 500 | 16.57 |
03:41 ET | 100 | 16.57 |
03:45 ET | 200 | 16.55 |
03:56 ET | 1000 | 16.57 |
03:57 ET | 200 | 16.565 |
03:59 ET | 2915 | 16.53 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Indivior PLC | 1.8B | 412.6x | --- |
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8B |
---|---|
Revenue (TTM) | $886.3M |
Shares Outstanding | 134.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.15 |
EPS | $-0.02 |
Book Value | $0.00 |
P/E Ratio | 412.6x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | 70.6x |
Operating Margin | 0.36% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.